Case Page


Case Status:    ONGOING    
On or around 12/04/2014 (Ongoing date of last review)

Filing Date: November 14, 2014

According to the law firm press release, this case alleges that the defendants made materially false or misleading statements with respect to the safety and efficacy of the Company’s drug Macrilen™. A November 6, 2014, press release by the Company brought these facts to light by announcing that the FDA had issued a Complete Response Letter refusing to approve the Company’s New Drug Application because of “the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: Canada


Ticker Symbol: AEZS
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. New Jersey
DOCKET #: 14-CV-07164
JUDGE: Hon. Peter G. Sheridan
DATE FILED: 11/14/2014
CLASS PERIOD END: 11/05/2014
  1. Abraham, Fruchter & Twersky LLP
    One Penn Plaza, Suite 2805, Abraham, Fruchter & Twersky LLP, NY 10119
    (212) 279-5050 (212) 279-3655 ·
  2. Kantrowitz, Goldhamer & Graifman, P.C.
    210 Summit Avenue, Kantrowitz, Goldhamer & Graifman, P.C., NJ 07645
    201-391-7000 201-307-1086 ·
No Document Title Filing Date